New Hope for Advanced Gastric Cancer
An article by Samuel Klempner, Medical Oncologist at Massachusetts General Hospital, was recently mentioned by Elvina Almuradova, Associate Professor at Medicana Health Group, on X:
“New Hope for Advanced Gastric Cancer!
DKN-01+tislelizumab+chemo shows a 73% response rate in advanced gastric cancer patients.
90% response in DKK1-high tumors.
11.3 months PFS, 19.5 months OS. Effective regardless of PD-L1!”
Authors: Samuel Klempner, Mohamad Bassam Sonbol, Zev Wainberg, Rachel Altura, Jaffer Ajani et al.
More posts featuring Elvina Almuradova.
Samuel J. Klempner is a member of the faculty at Harvard Medical School and Massachusetts General Hospital. He conducts clinical trials and translational research focused on new targeted agents and immunotherapies, and is active in the gastroesophageal cancer community, serving on the advisory boards of Debbie’s Dream Foundation and Hope for Stomach Cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023